Checkpoint Therapeutics, Inc. (CKPT)
NASDAQ: CKPT · Real-Time Price · USD
3.500
+0.120 (3.54%)
Nov 21, 2024, 12:37 PM EST - Market open
Checkpoint Therapeutics Employees
Checkpoint Therapeutics had 23 employees as of December 31, 2023. The number of employees decreased by 1 or -4.17% compared to the previous year.
Employees
23
Change (1Y)
-1
Growth (1Y)
-4.17%
Revenue / Employee
$2,043
Profits / Employee
-$2,020,348
Market Cap
157.55M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Organigram Holdings | 984 |
Nutex Health | 800 |
Adaptimmune Therapeutics | 449 |
Adverum Biotechnologies | 121 |
EUDA Health Holdings | 106 |
Myomo | 106 |
KORU Medical Systems | 82 |
Achieve Life Sciences | 22 |
CKPT News
- 6 days ago - Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date - Seeking Alpha
- 8 days ago - Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 2 months ago - Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 - GlobeNewsWire
- 2 months ago - Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success - Seeking Alpha
- 3 months ago - Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 4 months ago - Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma - GlobeNewsWire
- 4 months ago - GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research - GlobeNewsWire